Overview

Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease

Status:
Completed
Trial end date:
2012-02-01
Target enrollment:
Participant gender:
Summary
This study is being conducted to determine the safety and effect on cognitive function of the investigational medication, EVP-6124, in individuals with mild to moderate probable Alzheimer's disease.
Phase:
Phase 2
Details
Lead Sponsor:
FORUM Pharmaceuticals Inc
Collaborator:
INC Research Limited
Treatments:
Nicotinic Agonists